Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469386 | 0.93 | TRPM8 (0.33) | PDE4BPDE4DAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15469414 | 0.93 | TRPM8 (0.33) | PDE4BPDE4DAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15469509 | 0.85 | BACE1 (0.34) | PDE4BPDE4DAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15467175 | 0.82 | TRPM8 (0.38) | TRPM8 | |
| SCHEMBL15467176 | 0.82 | TRPM8 (0.38) | TRPM8 | |
| SCHEMBL16418774 | 0.81 | NOS3 (0.33) | BACE1AKT1AKT2TRPM8RAB9A | |
| SCHEMBL15469503 | 0.80 | AKR1B10 (0.34) | PDE4BPDE4DAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15469501 | 0.79 | BACE1 (0.32) | AKR1B10AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15469508 | 0.79 | AKR1B10 (0.33) | PDE4BPDE4DAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15469511 | 0.79 | GRM4 (0.33) | BACE1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PDE4B 2976/4885PDE4D 1323/4885AKR1B10 3940/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | PDE4B 2976/4885PDE4D 1323/4885AKR1B10 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.